Acurx Pharmaceuticals, Inc. carries no debt; cash flow comfortably covers obligations.

Acurx Pharmaceuticals, Inc.'s free cash flow has decreased 65.27K% from $-10.38M last year to $-6.79B, signaling decreasing performance

Acurx Pharmaceuticals, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Acurx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Acurx Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Acurx Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Acurx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Acurx Pharmaceuticals, Inc.'s short-term assets of $7.69M exceed its short-term liabilities of $2.42M

Acurx Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Acurx Pharmaceuticals, Inc.'s return on equity of -153.93%, is lower than 15.00%, indicating bad performance

Acurx Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Acurx Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Acurx Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Acurx Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Acurx Pharmaceuticals, Inc.'s yearly earnings has increased -43.51% since last year from $-14.10M to $-7.97M, signaling increasing performance

Acurx Pharmaceuticals, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -108.82% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Acurx Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Acurx Pharmaceuticals, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Acurx Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Acurx Pharmaceuticals, Inc. is undervalued relative to its fair value price of 3.69K based on Discounted Cash Flow model

Acurx Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Acurx Pharmaceuticals, Inc. is undervalued relative to its fair value price of 4.73K based on EBITDA multiple model

Acurx Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Acurx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Acurx Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Acurx Pharmaceuticals, Inc. has a price-to-book ratio of 0.33x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Acurx Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue